Evidence map›Paper›PMID 38478346›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Isolating Circulating Cancer Stem Cells (CCSCs) from Human Whole Blood.

Carla Kantara, Pomila Singh

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Carla KantaraDepartments of Neuroscience and Cell Biology and Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, TX, USA.
Pomila SinghDepartments of Neuroscience and Cell Biology and Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, TX, USA. posingh@utmb.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measuring circulating tumor cells (CTCs) or circulating cancer stem cells (CCSCs) in blood, which shed from primary tumors, is a noninvasive method to screen and/or diagnose patients with a high risk of developing metastatic cancers or relapse. Here, we describe an optimized and standardized laboratory method for isolating CCSCs from human blood samples, using cancer-specific stem cell biomarkers (Kantara et al., Lab Invest 95:100-112, 2015). When performing this technique, 0-1 circulating epithelial tumor cells/mL blood should be expected in patients free of malignant adenocarcinomas compared to over 3 circulating cancer stem cells/mL blood in patients positive for malignant adenocarcinomas (Kantara et al., Lab Invest 95:100-112, 2015).

Indexed as

AdenocarcinomaNeoplastic Cells, CirculatingBiomarkersBiomarkers, TumorCell Line, TumorHumansNeoplasm Recurrence, LocalNeoplastic Stem CellsBiomarkersBiomarkers, TumorBuffy coatCancer stem cell biomarkersCirculating cancer stem cellsDepletionHuman bloodImmunofluorescenceRed blood cellsSpheroidsWhite blood cells

Identifiers

PMID38478346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.